Bristol-Myers Drops as Test Results Fall Flat

ViroPharma plunges after FDA rejects Picovir drug; Schering AG will buy Collateral Therapeutics; plus more of today's stocks in the news

Merrill Lynch downgraded Bristol Myers (BMY ), and shares of the drug maker dived after unveiling less-than-superior test results for its hypertension drug Vanlev.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.